Dupilumab demonstrated its clinical efficacy in patients with both severe allergic asthma, defined by total serum IgE > 30 IU/mL and > 1 perennial aeroallergen-specific IgE >0.35 kU/L at baseline, and not allergic. This evidence concerns the gene IGHE and allergic asthma.